Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Study Summary

The primary purpose of this study is to characterize the safety and tolerability of tucatinib (MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma (GEC), and colorectal cancer.

Conditions

Metastatic HER2+ Advanced Breast Cancer Breast Neoplasms Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)Colorectal Cancer

Interventions / Drugs

Tucatinib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment25 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.190508+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.